Filed: 04/27/2001

Group Art Unit: 1648

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:** 

Claim 1 (canceled)

Claim 2 (withdrawn): The expression plasmid of claim 42 wherein the pol I promoter is

proximal to the polyadenylation signal and the pol I terminator sequence is proximal to the pol II

promoter.

Claim 3 (withdrawn): The expression plasmid of claim 42 wherein the pol I promoter is

proximal to the pol II promoter and the pol I terminator sequence is proximal to the

polyadenylation signal.

Claim 4 (withdrawn): The expression plasmid of claim 42 wherein the plasmid has a

map selected from the group consisting of pHW2000, pHW11 and pHW12.

Claim 5 (withdrawn): An expression plasmid comprising viral cDNA corresponding to a

genomic segment of an influenza virus, wherein the cDNA is inserted between an RNA

polymerase I (pol I) promoter and a regulatory element for the synthesis of vRNA or cRNA with

an exact 3' end, which are in turn inserted between an RNA polymerase II (pol II) promoter and

a polyadenylation signal, and wherein the cDNA only encodes an influenza viral protein.

3

Docket No.: 02427/100G772-US1

Filed: 04/27/2001 Group Art Unit: 1648

Claim 6 (canceled)

Claim 7 (withdrawn): The expression plasmid of claim 5, wherein the influenza virus is

an influenza A virus.

Claim 8 (withdrawn): The expression plasmid of claim 7, wherein the influenza viral

genomic segment (i) encodes a protein selected from the group consisting of a viral polymerase

complex protein, M protein, and NS protein; and (ii) is derived from a strain well adapted to

grow in cell culture or from an attenuated strain, or both.

Claim 9 (withdrawn): The expression plasmid of claim 5, wherein the virus is an

influenza B virus.

Claim 10 (withdrawn): The expression plasmid of claim 8 wherein the plasmid has a

map selected from the group consisting of pHW241-PB2, pHW242-PB1, pHW243-PA,

pHW245-NP, pHW247-M, and pHW248-NS.

Claim 11 (withdrawn): The expression plasmid of claim 8 wherein the plasmid has a

map selected from the group consisting of pHW181-PB2, pHW182-PB1, pHW183-PA,

pHW185-NP, pHW187-M, and pHW188-NS.

Claim 12 (withdrawn): The expression plasmid of claim 7, wherein the influenza viral

genomic segment comprises a gene selected from the group consisting of a hemagglutinin (HA)

gene and a neuraminidase (NA) gene.

Claim 13 (withdrawn): The expression plasmid of claim 12, wherein the influenza gene

is from a pathogenic influenza virus strain.

4

Docket No.: 02427/100G772-US1

Filed: 04/27/2001

Group Art Unit: 1648

Claim 14 (withdrawn): The expression plasmid of claim 12, wherein the plasmid has a

map selected from the group consisting of pHW244-HA, pHW246-NA, pHW184-HA, and

pHW186-NA.

Claim 15 (previously presented): A composition which generates infectious influenza

viruses from cloned viral cDNA comprising a set of plasmids wherein each plasmid comprises

one viral genomic segment, and wherein viral cDNA corresponding to the viral genomic segment

is inserted between an RNA polymerase I (pol I) promoter and a regulatory element for the

synthesis of vRNA or cRNA with an exact 3' end, which results in expression of vRNA or

cRNA, which are in turn inserted between an RNA polymerase II (pol II) promoter and a

polyadenylation signal, which results in expression of viral mRNA and a corresponding viral

protein, wherein the expression of the full set of vRNAs or cRNAs and viral proteins results in

assembly of an infectious influenza virus.

Claim 16 (previously presented): The composition of claim 44, wherein the pol I

promoter is proximal to the polyadenylation signal and the pol I terminator sequence is proximal

to the pol II promoter.

Claim 17 (previously presented): The composition of claim 44, wherein the pol I

promoter is proximal to the pol II promoter and the pol I terminator sequence is proximal to the

polyadenylation signal.

Claim 18 (canceled)

5

Docket No.: 02427/100G772-US1

Filed: 04/27/2001

Group Art Unit: 1648

Claim 19 (previously presented): The composition of claim 15, wherein the influenza

virus is an influenza A virus.

Claim 20 (previously presented): The composition of claim 15, wherein the influenza

virus is an influenza B virus.

Claim 21 (previously presented): The composition of claim 19, wherein the viral

genomic segment (i) encodes a protein selected from the group consisting of a viral polymerase

complex protein, M protein and NS protein; and (ii) is derived from a strain well adapted to grow

in cell culture or from an attenuated strain, or both.

Claim 22 (previously presented): The composition of claim 19, wherein the viral

genomic segment comprises hemagglutinin (HA) gene, or neuraminidase (NA) gene, or both;

wherein said genes are from a pathogenic influenza virus.

Claim 23 (previously presented): The composition of claim 19 wherein said composition

comprises one or more plasmids having a map selected from the group consisting of pHW241-

PB2, pHW242-PB1, pHW243-PA, pHW244-HA, pHW245-NP, pHW246-NA, pHW247-M, and

pHW248-NS.

Claim 24 (previously presented): The composition of claim 19, wherein said

composition comprises one or more plasmids having a map selected from the group consisting of

pHW181-PB2, pHW182-PB1, pHW183-PA, pHW184-HA, pHW185-NP, pHW186-NA,

pHW187-M, and pHW188-NS.

Claim 25 (previously presented): A host cell comprising the composition of claim 15.

6

Docket No.: 02427/100G772-US1

Serial No.: 09/844,517 Filed: 04/27/2001

Group Art Unit: 1648

Claim 26 (previously presented): A host cell comprising the composition of claim 20.

Claim 27 (previously presented): A host cell comprising the composition of claim 19.

Claim 28 (previously presented): A host cell comprising the composition of claim 22.

Claim 29 (currently amended): A method for producing an <u>infectious</u> influenza virus virion, which method comprises culturing the host cell of claim 25 under conditions that permit production of viral proteins and vRNA or cRNA, whereby an infectious influenza virus is produced.

Claims 30-31 (canceled)

Claim 32 (currently amended): A method for producing a pathogenic influenza virion, which method comprises culturing the host cell of claim 28 under conditions that permit production of viral proteins and vRNA or cRNA, whereby a pathogenic infectious influenza virus is produced.

Claims 33-38 (canceled)

Claim 39 (currently amended): A method for generating an attenuated influenza virus, which method comprises:

- (a) mutating one or more viral genes in the composition of claim 15; and
- (b) determining whether infectious influenza viruses produced by the composition upon introduction into a suitable host cell are attenuated.

7

Serial No.: 09/844,517 Filed: 04/27/2001

Group Art Unit: 1648

STOUP AIT OILL. TO

Claims 40-41 (canceled)

Claim 42 (withdrawn): The expression plasmid of claim 5, wherein the regulatory

element for the synthesis of vRNA or cRNA with an exact 3' end is an RNA polymerase I (pol I)

terminator sequence.

Claim 43 (withdrawn): The expression plasmid of claim 5, wherein the regulatory

element for the synthesis of vRNA or cRNA with an exact 3' end is a ribozyme sequence.

Claim 44 (previously presented): The composition of claim 15, wherein the regulatory

element for the synthesis of vRNA or cRNA with an exact 3' end is an RNA polymerase I (pol I)

terminator sequence.

Claim 45 (previously presented): The composition of claim 15, wherein the regulatory

element for the synthesis of vRNA or cRNA with an exact 3' end is a ribozyme sequence.

8

Docket No.: 02427/100G772-US1 {W:\02427\100G772000\00294702.DOC \*02427100G772000\* }